<SEC-DOCUMENT>0001144204-16-133030.txt : 20161110
<SEC-HEADER>0001144204-16-133030.hdr.sgml : 20161110
<ACCEPTANCE-DATETIME>20161110104126
ACCESSION NUMBER:		0001144204-16-133030
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161110
DATE AS OF CHANGE:		20161110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		161986490

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v452750_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>November 10, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>ABEONA THERAPEUTICS INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 30%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>0-9314</U></B></FONT></TD>
    <TD STYLE="width: 35%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>3333 Lee Parkway, Suite 600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Dallas, TX 75219</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(214)-665-9495</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial
Condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 10, 2016, Abeona Therapeutics
Inc. issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2016.
The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in Item&nbsp;2.02 of this
Current Report on Form&nbsp;8-K and Exhibit&nbsp;99.1 attached hereto shall not be deemed &ldquo;filed&rdquo; for purposes of Section&nbsp;18
of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements
and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 15%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 80%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Press release dated November 10, 2016, entitled &ldquo;Abeona Therapeutics Inc. Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Abeona Therapeutics Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 51%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 30%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stephen B. Thompson</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Stephen B. Thompson</FONT><BR>
<FONT STYLE="font-size: 10pt">Vice&nbsp;President&nbsp;Finance </FONT><BR>
<FONT STYLE="font-size: 10pt">Chief&nbsp;Accounting Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: November 10, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Exhibit Number </U></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 15%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; width: 80%">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Press release dated November 10, 2016, entitled &ldquo;Abeona Therapeutics Inc. Announces Third Quarter 2016 Financial Results and Recent Clinical Highlights&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v452750_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 133px; width: 367px"></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Abeona Therapeutics Announces Third Quarter
2016 Financial Results and Recent Clinical Highlights </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><I>Investor
Conference Call to be held Friday, November 18 at 10:30 am ET</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEW YORK, NY and CLEVELAND, OH</B> -
November 10, 2016 -- Abeona Therapeutics Inc. (NASDAQ: ABEO) <FONT STYLE="background-color: white">a clinical-stage biopharmaceutical
company focused on developing therapies for life-threatening rare genetic diseases</FONT>, today announced financial results for
the third quarter. The Company will provide investors an update on recent and ongoing business activities and an overview of its
3Q16 financials on, Friday, November 18 at 10:30 am (Eastern). Interested parties are invited to participate in the call by dialing
877-269-7756 (toll free domestic) or 201-689-7817 (international).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;During the third quarter of 2016,
we have made significant progress advancing our clinical gene therapy programs addressing serious genetic diseases and showcased
the strengths of our clinical and regulatory capabilities. Notably, we demonstrated promising safety and bio-potency in the low-dose
cohort for ABO-102 and received Fast Track designation for the program and Orphan Drug Designation in the European Union where
we are expanding clinical studies,&rdquo; stated Timothy J. Miller, Ph.D. &ldquo;In addition, <FONT STYLE="background-color: white">our
strategic work in adding the AIM<SUP>TM </SUP>vector platform, an AAV capsid portfolio from University of North Carolina at Chapel
Hill, positions us well for advancing next generation proprietary AAV gene therapies.</FONT>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Third Quarter Summary Financial Results:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Cash position:</B> Cash, cash equivalents and marketable securities as of September 30, 2016
were $31.2 million, compared to $34.3 million as of June 30, 2016. Net cash used in operating activities in the Nine Months Ended
September 30, 2016 was $9.6 million as compared to $7.5 million in the same period in 2015, an increase of $2.1 million.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Offering:</B> On November 1, 2016, we closed an underwritten public offering of 6,000,000 shares
of common stock, at a public offering price of $7.00 per share. The gross proceeds to the Company were $42,000,000 million, before
deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Revenues:</B> Revenues were $184 thousand for the third quarter of 2016, compared to $285 thousand
in the third quarter of 2015. Revenues consisted of a combination of royalties from marketed products, primarily MuGard&reg;, and
recognition of deferred revenues related to upfront payments from early license agreements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.85pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Loss per share:</B> Loss per share was $0.08 for the third quarter of 2016, compared to a loss
per share of $0.19 in the comparable period in 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;The third fiscal quarter of 2016
brought significant advancements in our goal of building a strong leadership position in the development of innovative therapies
for rare diseases,&rdquo; stated Steven H. Rouhandeh, Executive Chairman. &ldquo;We are excited about the initial biopotency signals
seen in our ABO-102 Phase 1/2 clinical trial for Sanfilippo syndrome Type A (MPS IIIA), initiation of the EB-101 Phase 2 study
for epidermolysis bullosa (EB), and the completion of a $42 million financing which provides us with ample runway to continue creating
significant value for the Company and its shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Abeona Recent Highlights:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">November 1, 2016: </FONT>Abeona announced closing of its
<FONT STYLE="background-color: white">$42 million </FONT>underwritten offering of common stock</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">October 25, 2016: Abeona announced receipt of Fast Track
designation from the FDA for ABO-102</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">October 18, 2016: </FONT>Abeona received Orphan Drug Designation
in the European Union for ABO-102 gene therapy in Sanfilippo syndrome Type A</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">October 14, 2016: </FONT>Abeona presented top-line data of
low-dose cohort for ABO-102 in Phase 1/2 clinical trial for MPS IIIA patients at Orphan Drugs and Rare Disease Congress October
19-20th in London, UK</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&sect;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">ABO-102 reduced GAG (heparan sulfate) in urine 57.6% +/-
8.2%</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&sect;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">ABO-102 reduced GAG (heparan sulfate) in the CSF 25.6% +/-
0.8% </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&sect;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Reduction in liver volume of 17.7% +/- 1.9%</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&sect;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">Reduction in spleen volume of 17.6% +/- 7.1%</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">October 7, 2016: Abeona announced JAMA publication of preclinical data supporting clinical translation
of Juvenile Batten Disease gene therapy</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">October 5, 2016: Abeona announced Data Safety Monitoring
Board approved ABO-102 dose escalation for second cohort in a Phase 1/2 Clinical Trial for Sanfilippo syndrome Type A </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">September 26, 2016: Abeona enrolled first patient in Phase
2 for EB-101, gene therapy clinical trial for epidermolysis bullosa</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">September 21, 2016: Abeona announced the exclusive worldwide
license of the AIM<SUP>TM</SUP> AAV capsid portfolio for next generation gene therapies from University of North Carolina at Chapel
Hill </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.85pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">September 8, 2016: Abeona enrolled 5<SUP>th</SUP> patient
in Phase 1 gene therapy clinical trial for epidermolysis bullosa</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>About
Abeona: </B></FONT>Abeona Therapeutics Inc.<FONT STYLE="background-color: white">&nbsp;is a clinical-stage biopharmaceutical company
developing gene and plasma-based therapies for life-threatening rare genetic diseases. Abeona&rsquo;s lead programs are ABO- 102 (AAV-SGSH)
and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively).
Abeona is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for
epidermolysis bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy
for treatment of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a
novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein
therapy pipeline, including SDF Alpha&trade; (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF&trade;
(Salt Diafiltration) ethanol-free process<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>For
more information, visit </B></FONT><FONT STYLE="background-color: white">www.abeonatherapeutics.com<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #26282A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #26282A"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #26282A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Investor Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Christine Berni-Silverstein</FONT><BR>
<FONT STYLE="background-color: white">Vice President, Investor Relations</FONT><BR>
Abeona Therapeutics Inc.<BR>
<FONT STYLE="background-color: white">+1 (212)-786-6212</FONT><BR>
<FONT STYLE="background-color: white">csilverstein@abeonatherapeutics.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Media Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andre&rsquo;a Lucca<BR>
Vice President, Communications &amp; Operations<BR>
Abeona Therapeutics Inc.<BR>
+1 (212)-786-6208</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">alucca@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #26282A"><FONT STYLE="background-color: white"><I>This
press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933,
as amended, and that involve risks and uncertainties. These statements are subject to numerous risks and uncertainties, including
but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact
of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals;
the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to
time in the Company&rsquo;s Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission.
The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update
them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future
developments or otherwise.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "% 6\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^J#7.H06
MMQ++9),Z/^ZBMI,LZ^IW8 -7ZP7UR/5K@66C26U]$2T5Y-;WJJ]J",!@ #D]
M<=.E'*Y;$R?F6[G7[&RN;6UNVDAN;D K&4+8SQ@D9'7BKJ75O+*T4=Q$\B_>
M17!(^HI+2V%I:0V_FRS>4NT23/O=O<GN:R%\*V%C)/>:5!';Z@RL(I7+,J,>
M^,U#YT]-42^=&]17#1:YJ/AF_P!GB34DG65"T<,,6YNOWLX  Z\<UUFEZK::
MS8K>6;EHB2OS*001U%*%6,G;9]@A5C)VV?8NT445H:!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!S/C35+FPTM$T_6],TN^=P5:_8 ,O<#KSTYP:
M=X+T\VNB+<3G29KNX8M)<Z9$J)*,\9( R>M1^+O!VC^((6OKS3I+N]MX6$2P
MS&-I ,D)GIR?7UKEO!GB+4='(TZ\\)?V)HD(9I+F61E6$]<LS_>)/''K70H\
MU*T=^NW^=V8.7+4O+;IO_2/4:*S=,\0Z/K22/INI6UR(N9/+D!*CU([5H(ZR
M('1@RGH5.0:P::T9LFGL4M8M4N-,G)^S+(B$I+<QATC/J<URGA*_OI=6^SRZ
M]8W, 5L6\2X+>Z_*N *Z77]4M]-T]Q-/%#),K)$98V="<=P!TK/\+:--9J]U
M=P:9OD ,4EI#M.T]<\#VKFFKU5;YF$U>JK?,Z6BB@D#J<5T'0%%(2!U.,TM
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MH?&+1P/WFD:RA]/LX_\ BJ9-\6XYU,>D^&M7NK@C"*\.U<]LXR:](HI\]/\
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MTN[6<1"95N(PN],XR,$]^QP>>E9GAOQ&;S2])BNWDN-2NXVD<1H/D0,1O?&
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M6$SJD=Z\($1W-M4]=P4DC!(QR*OZCK4&G75O:>1<7-U<!F2"W0,VU<98Y(
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
